TAXOL

NSC - 125973

SMILES: CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(=O)C)[C@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7)C(=C1C5(C)C)C

Other Names: Taxol ®, Paclitaxel

CAS Registry Number: 33069-62-4

Molecular Formula: C47H51NO14    M.W.: 853.9

Chemical Name: Q-(Benzoylamino)-a-hydroxy-benzenepropanoic acid, 6, 12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,
9,10,11,12,12a,12b- dodecahydro- 4,11- dihydroxy-4a,8,13,13-tetra-methyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[ 1,2-b]oxet-9-y1
ester, [2aR42aa,4f3,443,6f3 *,(3S *),lla,12a,12aa,12ba]]-

Description: Taxol is a poorly soluble plant product isolated from
Taxus brevifolia.

How Supplied: Injection, 30 mg, ampule/vial: 6 mg/mL, 5 mL,
in polyethoxylated castor oil (Cremophor EL®) 50%, and
dehydrated alcohol, USP, in 5 mL flint ampules/vials.

Solution Preparation: Taxol concentrations from 0.3 mg/mL to
1.2 mg/mL may be obtained by diluting the solution with either
0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection,
USP.

CAUTION: PVC bags and sets should be avoided due to
appreciable leaching of DEHP(1,2,3). This solution must
be diluted before use and given by slow intravenous
infusion.

NOTE: A small number of fibers (within acceptable levels of the
USP Particulate Matter Test for LVPs) have been observed after
dilution. Therefore, inline filtration is necessary with all taxol
infusions. Solutions exhibiting excessive particulate formation
should not be used. Analyses of solutions filtered through
IVEX -2® and IVEX- HP®(Abbott) 0.2 pm filters showed no
appreciable loss of potency.

Storage: Refrigerate the intact ampules and vials (2-8 °C).

Stability: Shelf-life surveillance of the ampules and vials is
ongoing. Three lots have maintained stability for at least 18
months at room temperature (22-25 °C). The intact vials were
unstable at elevated temperature (50 °C).

Solutions of taxol diluted to the above concentrations are both
chemically and physically stable for at least 27 hours at room
temperature. All solutions exhibit a slight haze which is common
to all products containing nonionic surfactants.

Route of Administration: Intravenous (slow infusion over one
hour or more)

References:

1. Waugh, W.N., Trissel, L.A., Stella, V.J. Stability,
Compatabilty, and Plasticizer Extraction of Taxol (NSC-125973)
Injected Diluted in Infusion Solutions and Stored in Various
Containers. Am J Hosp Pharm 48:1520-1524, 1991.

2. Harris, G.W. Di(2-ethylhexyl) phthalate (DEHP) in
Medical Products. Proceedings of the Conference on Phthalates,
National Toxicology Program /Interagency Regulatory Liaison
Group, June 9, 1981. pp 179-195

3. Jaeger, R.J., Rubin, R.J. Migration of a Phthalate Ester
Plasticizer from Polyvinyl Chloride Blood Bags into Stored Human
Blood and Its Localization in Human Tissues. N.Engl J Med
287:1114-1118, 1972.